Cargando…

Recurrence of skin infections in patients treated with telavancin versus vancomycin for complicated skin and soft tissue infections in a New Orleans emergency department

Detalles Bibliográficos
Autores principales:	Dunbar, L, Sibley, D, Hunt, J, Weintraub, S, Marr, A, Ramirez, J, Edler, R, Thompson, H, Kitt, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4088400/ http://dx.doi.org/10.1186/cc6250

Ejemplares similares

Role of telavancin in treatment of skin and skin structure infections
por: Bonkowski, Joseph, et al.
Publicado: (2010)

A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)
por: Dunbar, Lala M, et al.
Publicado: (2008)

Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections
por: Jafari Saraf, Lida, et al.
Publicado: (2011)

Efficacy of telavancin for treatment of surgical site infections
por: Wilson, SE, et al.
Publicado: (2008)

Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens
por: Rubinstein, Ethan, et al.
Publicado: (2011)

Emerging vancomycin-non susceptible coagulase negative Staphylococci associated with skin and soft tissue infections
por: Akinduti, Paul A., et al.
Publicado: (2022)

Clinical Management of Skin and Soft Tissue Infections in the U.S. Emergency Departments
por: Mistry, Rakesh D., et al.
Publicado: (2014)

1323. Efficacy and Safety of Telavancin Compared to Vancomycin for Cystic Fibrosis Pulmonary Exacerbation in Adults
por: Shorman, Mahmoud, et al.
Publicado: (2021)

Update on the emerging role of telavancin in hospital-acquired infections
por: Nnedu, Obinna N, et al.
Publicado: (2015)

The Efficacy and Safety of Arbekacin and Vancomycin for the Treatment in Skin and Soft Tissue MRSA Infection: Preliminary Study
por: Hwang, Ji-Hee, et al.
Publicado: (2013)

678 Ceftaroline vs Vancomycin in Treatment for Skin and Soft Tissue Infections (SSTI) in Obese Patients
por: Nguyen, Hao, et al.
Publicado: (2014)

Clinical Experience with Telavancin for the Treatment of Patients with Bone and Joint Infections: Preliminary Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles, et al.
Publicado: (2017)

Experience with High Dose Once-daily Vancomycin for Patients with Skin and Soft-tissue infections in an Ambulatory Setting
por: Wong, Maggie, et al.
Publicado: (2017)

192. The Use of Area Under the Curve to Determine Therapeutic Vancomycin Dosing in Skin and Soft Tissue Infections
por: Dea, Lauren, et al.
Publicado: (2020)

Real-World Clinical Use and Outcomes of Telavancin for the Treatment of Bone and Joint Infections: Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles R., et al.
Publicado: (2021)

A Syndromic Approach to Emergency Department Surveillance for Skin and Soft Tissue Infections
por: May, Larissa, et al.
Publicado: (2013)

Treatment Failure Outcomes for Emergency Department Patients with Skin and Soft Tissue Infections
por: May, Larissa S., et al.
Publicado: (2015)

Guidelines vs Actual Management of Skin and Soft Tissue Infections in the Emergency Department
por: Kamath, Rahul S, et al.
Publicado: (2018)

Factors Associated with Decision to Hospitalize Emergency Department Patients with Skin and Soft Tissue Infection
por: Talan, David A., et al.
Publicado: (2015)

Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin
por: Eckmann, Christian, et al.
Publicado: (2010)

2369. Clinical Experience With Telavancin for Treatment of Patients With Monomicrobial S. aureus Infections (Vancomycin MIC ≥1 μg/mL) From TOUR™
por: Jacobs, Micah, et al.
Publicado: (2018)

Skin and soft tissue infections in the elderly
por: Falcone, Marco, et al.
Publicado: (2023)

Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Bressler, Adam M., et al.
Publicado: (2019)

Evaluation of Skin and Soft Tissue Infection Outcomes and Admission Decisions in Emergency Department Patients
por: Black, Nicholas, et al.
Publicado: (2018)

The impact of initial antibiotic therapy (linezolid, vancomycin, daptomycin) on hospital length of stay for complicated skin and soft tissue infections
por: Szczypinska, Ewa, et al.
Publicado: (2013)

Optimizing the Dosing Regimens of Tigecycline against Vancomycin-Resistant Enterococci in the Treatment of Intra-abdominal and Skin and Soft Tissue Infections
por: Santimaleeworagun, Wichai, et al.
Publicado: (2020)

2404. Telavancin (TLV) and Vancomycin (VAN) Activity and Impact on Mechanical Properties When Incorporated into Orthopedic Bone Cement
por: Bishop, Aaron, et al.
Publicado: (2018)

The Effect of Systemic Antibiotics for Suppurative Skin and Soft Tissue Infections on the Skin Microbiome
por: Chan, Alfred A, et al.
Publicado: (2022)

675 Outcomes of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) by vancomycin dosing regimen and vancomycin trough serum concentrations in the DISCOVER Program
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

The skin and soft tissue infections in hematological patients
por: Ungaro, Riccardo, et al.
Publicado: (2020)

1386. Prescribing Patterns of Skin and Soft Tissue Infections in Patients Discharged from the Emergency Department
por: Feist, Jacqueline, et al.
Publicado: (2022)

Telavancin: A novel lipoglycopeptide antibiotic
por: Damodaran, S. E., et al.
Publicado: (2011)

Chemical Stability of Telavancin in Elastomeric Pumps()
por: Sand, Patrick, et al.
Publicado: (2015)

In vitro susceptibility of methicillin-resistant Staphylococcus aureus isolates from skin and soft tissue infections to vancomycin, daptomycin, linezolid and tedizolid
por: Vanegas Múnera, Johanna Marcela, et al.
Publicado: (2017)

Prevalence and demographics of methicillin resistant Staphylococcus aureus in culturable skin and soft tissue infections in an urban emergency department
por: Jacobus, Christian H, et al.
Publicado: (2007)

291 Efficacy and safety of telavancin in the treatment ofram-positive bloodstream infections in cancer patients
por: Chaftari, Anne-Marie, et al.
Publicado: (2014)

All purulence is local – epidemiology and management of skin and soft tissue infections in three urban emergency departments
por: Merritt, Chris, et al.
Publicado: (2013)

1555. Risk of Developing Acute Kidney Injury in Patients Receiving Piperacillin–Tazobactam and Vancomycin Compared with Those on Piperacillin–Tazobactam and Telavancin
por: Reilly, Joseph, et al.
Publicado: (2019)

442. Risk Score for Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections
por: Jorgensen, Sarah C J, et al.
Publicado: (2019)

A Multicenter Evaluation of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections
por: Jorgensen, Sarah C. J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_59n5k2qr877sm2mke7vug2fnr3